GSK3326595, a PRMT5 inhibitor, is in phase I trials for non-Hodgkin lymphoma, while other PRMT5 inhibitors, such as the PRT543 series, are in phase I trials for relapsed/refractory advanced solid tumors, and the PRT811 series is in phase I trials for relapsed glioma, advanced solid tumors, and CNS lymphoma. This evidence concerns the gene PRMT5 and primary central nervous system lymphoma.